Global, regional, and national incidence and mortality of congenital birth defects from 1990 to 2019

Infant congenital heart disease prevalence and mortality in French Guiana: a population-based study

“…For mainland France, the 2005–2008 EPICARD (Etude EPIdémiologique sur le devenir des enfants porteurs de CARDiopathies congénitales) study is the only well-designed population-based neonatal and perinatal prospective CHD cohort available to date, based in the Greater Paris area (Paris and its surrounding suburbs), and integrating long-term follow-up of all CHD cases (live births, pregnancy terminations, fetal deaths) diagnosed in the prenatal period or up to one year of age in birth cohorts between May 2005 and April 2008. 3 , 4 , 5 , 6 Due to methodological differences in eligibility criteria between our study cohort and EPICARD (notably non-inclusion of minor CHD types for the French Guianese analysis), overall live birth CHD prevalence could not be directly compared between French Guiana (65.2 [95% CI: 64.7–65.7]/10,000) and mainland France (74.8 [95% CI: 87.0–93.6]/10,000). The same goes for overall CHD-related infant mortality (French Guiana: 9.4 [95% CI: 9.1–9.7]/10,000 vs. EPICARD: 4.8 [95% CI: 4.7–5.0]/10,000).…”

“…The prevalence of congenital heart diseases (CHD) remains geographically variable, with a global estimate of 80–90/10,000 live births. 1 , 2 , 3 In light of the very heterogeneous worldwide CHD spectrum, the current paucity of large structured population databases might limit the precise evaluation of CHD-related neonatal or infant morbidity and mortality, especially in low-resource settings. 4 Until now, only a few studies have carefully assessed the prevalence and mortality of newborns with either simple or complex CHD, 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 while other authors have either limited their focus to the most severe or the most frequent defects, or to premature and very low-weight infants.…”

Congenital Malformations in the Moroccan Surveillance System: Contribution to Prevalence Estimation

“…These objectives cannot be achieved without thinking about CMs, which represent a serious public health problem on a global scale. Internationally, these anomalies were the fourth leading cause of death in children under 5 in 2019, contributing to around 10% of all deaths [ 15 ].…”

The congenital birth defects burden in children younger than 14 years of age, 1990 – 2019: An age-period-cohort analysis of the global burden of disease study

“…CBDs are a leading cause of neonatal mortality and contribute to long-term disability, with varying degrees of severity affecting individual quality of life, family dynamics, and health care systems [ 2 ]. The etiological landscape of CBDs is multifaceted, including genetic, environmental, and maternal health factors, which can influence the occurrence and severity of these conditions [ 3 ]. Worldwide, it is estimated that CBDs affect approximately six percent of infants, leading to the demise of 240 000 newborns within the first 28 days of life and causing the death of an additional 170 000 children between the ages of one and 59 months annually [ 3 ].…”

“…The etiological landscape of CBDs is multifaceted, including genetic, environmental, and maternal health factors, which can influence the occurrence and severity of these conditions [ 3 ]. Worldwide, it is estimated that CBDs affect approximately six percent of infants, leading to the demise of 240 000 newborns within the first 28 days of life and causing the death of an additional 170 000 children between the ages of one and 59 months annually [ 3 ]. In the year 2019, these defects emerged as the fourth leading cause of mortality among children under the age of five, comprising close to 10% of all fatalities in this age group [ 4 ].…”